TGFB1 and neoplasm: As shown in Figure 6A, in passage 4 of the HS diet cohort from the Py230-C57Bl/6J model, the combination of anti-TGFβ mAb with anti-CTLA4 mAb significantly reduced the tumor progression (day 28, 172 ± 76 mm3 vs. 783 ± 104 mm3, isotype control mAb, p < 0.05) compared to individual anti-CTLA4 mAb treatment (day 28, 498 ± 53 mm3, p < 0.05) or anti-TGFβ mAb treatment alone (day 28, 629 ± 76 mm3, p < 0.05).